Compounds that inhibit factor Xa activity

Compounds of the Formula (I)

• wherein
• X is H, Cl, Br, —C(═NR1)NH2, —CH2NH2, —NH—C(═NR1)NH2, —S—C(═NR1)NH2, —NH—C(═NH)—C(═NH)NH2, —C(═NH)SR1, —NH2, —C(═N—NH2)NH2, wherein R1 is —H, —OH, —C(═O)OR2, alkyl, aralkyl, aralkyloxy, aryloxy or a heteroalkyl group, wherein R2 is alkyl, heteroalkyl, a carbocycle, heterocycloalkyl, aryl, heteroaryl or aralkyl;
• Y is O, S, SO, SO2, SO2NH, PO2NH, NR10, CO or CR8R9 wherein R8, R9 and R10 are independently H, alkyl, heteroalkyl, carbocycle, heterocycloalkyl, aryl, heteroaryl, aralkyl or heteroarylalkyl with the exception, that if Y is NR10, X is not —(═NR1)NH2;
• Ar is aryl, heteroaryl, heteroarylalkyl or aralkyl wherein X is directly attached to the aromatic ring system;
• R3 is H, an alkyl group, a heteroalkyl group, a carbocycle, a heterocycloalkyl group, an aryl group, a heteroaryl, group, a heteroarylalkyl group or an aralkyl group;
• R4 is H, alkyl, heteroalkyl, a carbocycle, heterocycloalkyl, aryl, heteroaryl, heteroarylalkyl or aralkyl;
• R5 is H, an alkyl group, a heteroalkyl group, a carbocycle, a heterocycloalkyl group, an aryl group, a heteroaryl group or an aralkyl group and
• R6 and R7 are independently H, alkyl, heteroalkyl, carbocycle, heterocycloalkyl, aryl, heteroaryl, aralkyl or heteroarylalkyl or are together members of a heterocycloalkyl ring system, or a heteroaryl ring system;
• or a pharmacologically acceptable salt, solvate, hydrate, prodrug or formulation thereof.